New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 12, 2013
09:05 EDTSTEMStemCells announce first transplant in phase 1,2 trial in AMD
StemCells announced dosing of the first high-dose patient in the company's Phase 1,2 clinical trial in dry age-related macular degeneration.The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with 1M HuCNS-SC cells. The first four patients each received a dose of 200K cells. An independent Data Safety Monitoring Committee conducted a review of the trial data to date, and found no safety issues to preclude the trial from proceeding to the high dose.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
18:49 EDTSTEMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:05 EDTSTEMStemCells initiated with a Buy at Cantor
Target $2.
May 18, 2015
10:01 EDTSTEMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:12 EDTSTEMStemCells initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated StemCells with a Buy rating and $1 price target. The firm is encouraged by StemCells preliminary data from early trials of dry age-related macular degeneration and chronic spinal cord injuries.
May 14, 2015
08:40 EDTSTEMStemCells announces positive top-line results of HuCNS-SC Phase I/II study
StemCells announced that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell, or HuCNS-SC, intramedullary transplantation in thoracic spinal cord injury. The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society, or ISCoS, and American Spinal Injury Association, or ASIA, meeting being held in Montreal, Canada. The abstract was selected as one of the top six platform submissions for the conference. The international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord and were in the early chronic stage of recovery. The severity of spinal cord trauma is classified by the ASIA Impairment Scale, or AIS, according to the degree of sensory and motor loss. Patients classified as AIS A, the most severe injury, have lost both sensory and motor function below the level of injury. AIS B patients are considered less severely injured because, although they also have no motor function below the level of injury, some limited sensory function is maintained. The protocol was specifically designed to test safety and preliminary efficacy across this spectrum of injury severity, and ultimately the trial transplanted seven AIS A and five AIS B patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use